Jun 02, 2020 / NTS GMT
Clive Tompkins - Finance News Network - Moderator
Good morning, everyone. Thank you for joining us for another Immutep investor call to discuss more clinical results from the company's lead product candidate, eftilagimod alpha. Clive Tompkins in Sydney here, your moderator for today. (Event Instructions)
I'd now like to hand you over to -- hand the call over to Marc Voigt, Immutep's CEO, to start the presentation. Marc, are you there?
Marc Voigt - Immutep Limited - Executive Director & CEO
Thank you, Clive, and welcome, everyone. Early in the morning in Australia, obviously, late in the afternoon in the US, and close to midnight in Europe. So we would like to thank all of you for joining us on the call today, and I hope that everyone is keeping safe and well with your families during the COVID-19 situation obviously still impacting our lives.
On today's webcast, we are excited to take you through the new data from our TACTI-002 and the INSIGHT-004 trial, which was just announced at the virtual ASCO conference. The data relates to our lead
Immutep TACTI-002 and INSIGHT Global Webcast Slides Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot